Sequent Scientific Limited has announced the allotment of 1,00,000 equity shares under its Employee Stock Option Plan 2020 (SeQuent ESOP 2020) scheme. The Nomination and Remuneration Committee approved this allotment through a resolution passed by circulation on December 30, 2025.

ESOP Allotment Details

The company has issued equity shares to eligible employees under the following terms:

The newly allotted equity shares will rank pari passu in all respects with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital:

The increase represents a marginal expansion of 0.023% in the total number of outstanding equity shares.

Corporate Governance

The allotment was executed following proper corporate governance procedures, with the Nomination and Remuneration Committee exercising its authority to approve the issuance. Company Secretary and Compliance Officer Yoshita Vora signed the regulatory filing, ensuring compliance with stock exchange requirements.

The company has duly informed both BSE Limited (Scrip code: 512529) and National Stock Exchange of India Limited (Symbol: SEQUENT) about this corporate action for their records and necessary market updates.

Sequent Scientific has announced the resignation of VP Ashish Kakabalia from his senior management position, effective December 23, 2025. The pharmaceutical company submitted the resignation intimation to BSE and NSE under Regulation 30 of SEBI Listing Regulations.

Executive Departure Details

Kakabalia served as Vice President - Business Development and Formulation and was designated as Senior Management Personnel. His resignation letter was dated December 23, 2025, making the departure effective immediately.

Regulatory Compliance

The company filed the resignation intimation with both stock exchanges as required under SEBI regulations. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, with the requisite documentation submitted to BSE (Scrip Code: 512529) and NSE (Scrip Code: SEQUENT).

Company Communication

The resignation letter was addressed to CEO Rajaram Narayanan of Alivira Animal Health Ltd. In his resignation communication, Kakabalia mentioned that the decision was made as per mutual discussion and understanding, expressing gratitude and best wishes to the company and its employees.

The pharmaceutical company confirmed that the resignation was processed according to regulatory requirements, with Company Secretary and Compliance Officer Yoshita Vora handling the formal disclosure procedures.